All In Biotech

Drug Trial Radar · NCT00211224

Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)

Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)

Last checked: Nov 20, 2026Latest source record: Dec 15, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

800

Actual

Start

Apr 2000

Primary completion

Not stated

Study completion Nov 2004

Sponsor

Lead sponsor
King's College LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Assistance Publique - Hôpitaux de Paris; University of Ulm; Aventis Pharmaceuticals
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus' syndromes of multiple system atrophy (MSA) and progressive supranuclear plasy (PSP). In addition to showing whether riluzole is helpful in MSA and PSP, NNIPPS will improve criteria for making an accurate and early diagnosis, for assessing the rate of progression, and will advance understanding of the biology of these disabling and progressive neurodegenerative diseases.

Conditions

  • Multiple System Atrophy
  • Progressive Supranuclear Palsy

Interventions

  • RiluzoleDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survival

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Psychiatry, King's College London

    London, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.